Holen Sie sich die Stockscreener-App
2.075
9.78%
-0.225
Vorhandelsmarkt:
2.33
0.255
+12.29%
Schlusskurs vom Vortag:
$2.30
Offen:
$2.33
24-Stunden-Volumen:
704.40K
Relative Volume:
4.05
Marktkapitalisierung:
$67.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-87.23M
KGV:
-0.6987
EPS:
-2.97
Netto-Cashflow:
$-82.77M
1W Leistung:
-23.71%
1M Leistung:
-42.84%
6M Leistung:
-87.46%
1J Leistung:
-69.17%
1-Tages-Spanne:
$2.07
$2.44
1-Wochen-Bereich:
$2.07
$2.83
52-Wochen-Spanne:
$2.07
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Vergleichen Sie PEPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
2.075 | 67.64M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
PepGen stock hits 52-week low at $2.21 amid market challenges - MSN
PepGen Inc. (NASDAQ:PEPG) Short Interest Down 14.1% in December - MarketBeat
PepGen stock hits 52-week low at $2.88 amid market challenges - Investing.com India
PepGen stock hits 52-week low at $2.88 amid market challenges By Investing.com - Investing.com South Africa
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - AccessWire
Jane Street Group LLC Purchases 6,254 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy - Yahoo Finance
Barclays PLC Has $189,000 Stock Position in PepGen Inc. (NASDAQ:PEPG) - Defense World
Geode Capital Management LLC Has $3.21 Million Stock Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Comments on PepGen’s FY2028 Earnings (NASDAQ:PEPG) - Defense World
Fmr LLC Sells 327,160 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Has Bullish Forecast for PepGen FY2028 Earnings - MarketBeat
FDA Pauses PepGen’s DMD Drug Trial in the US - AJMC.com Managed Markets Network
PepGen stock craters 35% on FDA clinical hold - MSN
PepGen (NASDAQ:PEPG) Downgraded by Bank of America to Underperform - Defense World
FDA halts PepGen's DMD trial; ongoing study continues By Investing.com - Investing.com Australia
PepGen stock touches 52-week low at $2.9 amid market challenges - Investing.com
FDA halts PepGen's DMD trial; ongoing study continues - Investing.com India
PepGen shares downgraded to Underperform by BofA amid uncertainty over clinical hold - Investing.com
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
PepGen stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
Déjà Vu for PepGen as FDA Places Hold on DMD Drug - BioSpace
PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold - MarketWatch
FDA Places Clinical Hold on PepGen's Phase 2 DMD Trial, Canadian Study Advances - StockTitan
When (PEPG) Moves Investors should Listen - Stock Traders Daily
Frazier Life Sciences Management L.P. Sells 800,094 Shares of PepGen Inc. (NASDAQ:PEPG) - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Bought by Janus Henderson Group PLC - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Acquired by Suvretta Capital Management LLC - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - Yahoo Finance
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development - Business Wire
Two new option listings and one option delisting on November 21st - TipRanks
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Simply Wall St
BofA lowers PepGen stock target as trial delays and competition weigh on outlook - Investing.com
Bank of America Cuts PepGen (NASDAQ:PEPG) Price Target to $6.00 - MarketBeat
PepGen price target lowered to $6 from $10 at BofA - TipRanks
Janus Henderson Group PLC's Strategic Acquisition of PepGen Inc Shares - GuruFocus.com
Leerink Partnrs Issues Positive Forecast for PepGen Earnings - MarketBeat
PepGen (NASDAQ:PEPG) Price Target Cut to $12.00 by Analysts at Wedbush - MarketBeat
PepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC Wainwright - MarketBeat
PepGen Inc (PEPG) Quarterly 10-Q Report - Quartz
PepGen reports Q3 EPS (66c), consensus (87c) - TipRanks
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - BioSpace
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate - Yahoo Finance
Objective long/short (PEPG) Report - Stock Traders Daily
PepGen to Participate in Upcoming Investor Conferences - Business Wire
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):